A5030363207- Helicobacter pylori-related gastroenterology studies
- Gastric Cancer Management and Outcomes
- Veterinary medicine and infectious diseases
- Gastroesophageal reflux and treatments
- Gastrointestinal disorders and treatments
- Lung Cancer Research Studies
- Inflammatory mediators and NSAID effects
- Neuroendocrine Tumor Research Advances
- Clostridium difficile and Clostridium perfringens research
- Diverticular Disease and Complications
- Tuberous Sclerosis Complex Research
- Abdominal Trauma and Injuries
- Colorectal Cancer Screening and Detection
- Abdominal vascular conditions and treatments
- Osteoarthritis Treatment and Mechanisms
- Neuroblastoma Research and Treatments
- Galectins and Cancer Biology
- Total Knee Arthroplasty Outcomes
- Esophageal Cancer Research and Treatment
National Taiwan University Hospital
2013-2023
Gastric neuroendocrine tumors (GNETs) are a heterogeneous group of neoplasm with varying biological characteristics. This study aimed to investigate the clinical features and outcomes GNET patients after endoscopic diagnosis treatment in multicenter registry. Patients GNETs confirmed histologically were recruited from 17 hospitals between January 2010 April 2016 Taiwan. Clinical, laboratory, radiological, endoscopic, pathological data, strategies, follow-up periods, survivals collected...
Carbon dioxide (CO2) insufflation during colonoscopy can significantly decrease abdominal pain and bloating after the procedure, but its impact on frequency duration of toilet use remains unknown. The aim this study was to assess CO2 screening colonoscopy.From 138 average-risk individuals who underwent March August 2013, 120 were enrolled randomized receive either or air at colonoscopy. Both colonoscopist participant blinded type gas used. Abdominal distension assessed using a visual analog...
Whether adjunctive N-acetylcysteine (NAC) may improve the efficacy of triple therapy in first-line treatment Helicobacter pylori infection remains unknown. Our aim was to compare 14-day with or without NAC for H. pylori.Between 1 January 2014 and 30 June 2018, 680 patients naïve were enrolled this multicenter, open-label, randomized trial. Patients randomly assigned receive [NAC-T14, dexlansoprazole 60 mg four times daily (q.d.); amoxicillin g twice (b.i.d.), clarithromycin 500 b.i.d., 600...